Understanding Peptide Sequences: One- and Three-Letter Codes

What is a peptide sequence?

A peptide sequence is a written representation of amino acid residues joined by peptide bonds in a defined order. For laboratory communication, the same sequence may be written with one-letter amino acid symbols, three-letter amino acid abbreviations, or full residue names.

These codes are not claims about biological activity, purity, safety, or suitability for any use. They are standardized chemical language used to describe molecular structure, compare database entries, design assays, interpret mass spectrometry data, and communicate with synthesis or analytical laboratories.

The conventions discussed here are based on recognized biochemical nomenclature from sources such as IUPAC-IUBMB recommendations, protein database conventions, and analytical chemistry practice. Where this article refers to sequence identification methods, the evidence level is in vitro analytical chemistry, not animal research, human observation, or clinical evidence.

Research Notice
This article discusses published scientific research. It is provided for educational purposes only and does not provide medical advice, dosing, administration or human-use instructions.

1. Single-letter amino acid codes in peptide notation

The single-letter amino acid code represents each of the 20 common proteinogenic amino acids with one capital letter. For example, alanine is A, glycine is G, lysine is K, proline is P, and valine is V. This is a nomenclature convention, not an experimental claim; its authority comes from standardized biochemical usage rather than from animal or human evidence.

Single-letter notation is compact, which makes it useful for database records, sequence alignments, computational tools, and long peptides or proteins. A sequence written as KPV is read residue by residue as lysine-proline-valine, from left to right unless another direction is explicitly stated.

Several letters are not used as standard one-letter symbols for the 20 common residues. B, Z, and J may appear in some databases as ambiguity codes, while X often indicates an unknown or unspecified residue. U represents selenocysteine and O represents pyrrolysine in contexts where those genetically encoded residues are being annotated.

Because single-letter notation is brief, it can also hide important details. It usually does not show protecting groups, counterions, salt form, isotopic labels, terminal modifications, disulfide connectivity, or non-standard residues unless additional annotations are provided.

2. Three-letter amino acid codes and residue names

The three-letter code gives a more explicit abbreviation for each residue. Alanine is Ala, glycine is Gly, lysine is Lys, proline is Pro, and valine is Val. The sequence KPV can therefore also be written as Lys-Pro-Val.

Three-letter notation is often easier for people reading short peptides, especially when residues have similar one-letter symbols or when the sequence includes modifications. For example, aspartic acid is Asp and glutamic acid is Glu, while asparagine is Asn and glutamine is Gln. The three-letter form reduces ambiguity for readers who are less familiar with single-letter codes.

The three-letter code also fits naturally with chemical annotations. A modified residue may be written with a descriptor such as phospho-Ser, acetyl-Lys, amidated C-terminus, or pyroglutamate, depending on the reporting standard used by the laboratory or database. These descriptions are structural annotations and do not by themselves establish biological function.

In analytical research, sequence assignments may be supported by in vitro techniques such as liquid chromatography, tandem mass spectrometry, Edman degradation, amino acid analysis, or nuclear magnetic resonance, depending on the molecule and study design. The evidence level for those sequence-confirmation statements is in vitro analytical chemistry.

3. Reading direction from N-terminus to C-terminus

Peptide sequences are conventionally written from the amino terminus to the carboxyl terminus, often called N-to-C direction. The left end is the N-terminus, and the right end is the C-terminus. This convention is a standardized notation rule rather than a biological efficacy claim.

For the sequence Ala-Gly-Lys, alanine is the N-terminal residue and lysine is the C-terminal residue unless the notation states otherwise. Reversing the order to Lys-Gly-Ala describes a different molecule because the covalent connectivity is different.

Terminal chemistry matters. A free N-terminus, an acetylated N-terminus, a free carboxyl C-terminus, and an amidated C-terminus are different structural descriptions. If a research protocol, certificate of analysis, or publication reports a terminal modification, that information should be read as part of the sequence identity.

Some publications use prefixes or suffixes such as Ac-, NH2, -amide, or -OH to show terminal groups. Researchers should check the methods section or supplementary information because notation styles vary among journals, vendors, databases, and synthesis facilities.

4. L-amino acids, D-amino acids, and non-standard residues

Most naturally encoded peptide and protein sequences use L-amino acids, with glycine being achiral. However, synthetic peptides may include D-amino acids or other non-standard residues for research purposes. This is a structural statement; where determined experimentally, the evidence level is in vitro analytical chemistry.

D-amino acids are commonly indicated with a lowercase d, a prefix such as D-, or a formatting convention such as d-Phe. Without explicit notation, readers should not assume that an unusual stereochemical form is present. Conversely, if D-residues are reported, the one-letter sequence alone may be insufficient to describe the molecule fully.

Non-standard residues may be written using expanded names, database identifiers, bracketed annotations, or three-letter-like abbreviations. Examples include norleucine, ornithine, beta-alanine, hydroxyproline, and many chemically modified residues. Because conventions differ, the safest interpretation comes from the complete structural description rather than a simplified shorthand.

Disulfide bonds are another common source of confusion. A sequence containing two cysteine residues does not automatically show whether they are reduced, paired with each other, or linked to other cysteines in a larger molecule. Disulfide connectivity is a structural feature that should be separately documented.

5. Common peptide sequence notation errors

One frequent error is treating a sequence name as a complete chemical identity. A short code may identify the residue order but omit salts, counterions, hydration state, stereochemistry, terminal groups, and modifications. For research reproducibility, those details can be important.

Another error is mixing one-letter and three-letter conventions without separators. KPV is clear as a single-letter sequence, while Lys-Pro-Val is clear as a three-letter sequence. A mixed string such as LysPV can be difficult to interpret unless a document defines its notation.

Researchers should also distinguish residue mass from free amino acid mass. When amino acids form peptide bonds, water is lost during bond formation, so the mass of a residue in a peptide is not the same as the mass of the isolated free amino acid. This statement is based on established chemical stoichiometry and is typically applied in in vitro analytical calculations.

Sequence similarity should not be interpreted as equivalent biological behaviour. Two peptides that differ by one residue, terminal group, stereochemical configuration, or modification may have different physicochemical properties in a given assay. Evidence for any functional claim would require appropriate experimental data and should not be inferred from notation alone.

What Does the Research Show?

The scientific literature supports peptide sequence notation as a standardized descriptive system, not as evidence of health effects or product performance. The strongest evidence relevant to sequence reading comes from biochemical nomenclature standards and in vitro analytical methods used to establish or verify molecular identity.

In vitro analytical chemistry: Mass spectrometry, chromatography, Edman degradation, amino acid analysis, and related methods can be used to investigate peptide identity, sequence, mass, and modifications under defined laboratory conditions.
Animal evidence: Animal studies may investigate biological mechanisms of specific peptides, but they are not needed to establish how single-letter or three-letter sequence notation is read.
Observational human evidence: Observational human data are not a basis for amino acid code definitions and should not be used to infer meaning from sequence notation.
Controlled human trial evidence: Clinical trials may evaluate specific authorised or investigational molecules in defined settings, but trial findings do not validate the composition or characteristics of any separate research product.
Established authorised clinical use: Some peptide or protein medicines have authorised clinical uses in specific jurisdictions, but those authorisations apply to regulated products and indications, not to sequence codes in general.

For laboratory professionals, the practical takeaway is to read peptide sequences as structured chemical descriptions. Start with the residue order, confirm N-to-C direction, identify terminal groups, check for stereochemistry and modifications, and avoid drawing biological conclusions from shorthand notation alone.

Related Research Product

As an example of a short peptide name that can be written in standard sequence notation, KPV corresponds to Lys-Pro-Val when referring to the molecule’s residue order.

Sources and further reading

IUPAC–IUB — amino acid and peptide nomenclature — Official naming and notation recommendations.
IUPAC–IUB — single-letter sequence symbols — Official one-letter-code recommendations.

Educational Disclaimer
This article is provided for scientific and educational purposes only. It does not describe or imply the safety, effectiveness or intended use of any Lux Peptides product.
Nothing in this article is intended to diagnose, treat, cure or prevent disease or provide instructions for human use.